	US 11,723,928 B2
	Using autologous mesenchymal stem cells to treat multiple system atrophy
Wolfgang Singer, Rochester, MN (US); and Phillip Low, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Aug. 12, 2022, as Appl. No. 17/886,730.
Application 17/886,730 is a continuation of application No. 15/736,644, granted, now 11,426,431, previously published as PCT/US2016/037632, filed on Jun. 15, 2016.
Claims priority of provisional application 62/175,628, filed on Jun. 15, 2015.
Prior Publication US 2023/0075604 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/28 (2015.01); A61P 25/28 (2006.01); A61K 9/00 (2006.01); A61K 35/12 (2015.01)

CPC A61K 35/28 (2013.01) [A61K 9/0085 (2013.01); A61P 25/28 (2018.01); A61K 2035/124 (2013.01)]

8 Claims

1. A method for treating multiple system atrophy at a disease stage having a Unified Multiple System Atrophy Rating Scale I (UMSARS I) score of 17 or less, wherein said method comprises intrathecally administering a composition comprising autologous mesenchymal stem cells to a human that was identified as having multiple system atrophy with a first UMSARS I score, wherein said first UMSARS I score is 17 or less, wherein said autologous mesenchymal stem cells are adipose derived mesenchymal stem cells or bone marrow derived mesenchymal stem cells, and wherein, at least three months following said administering step, said human has a second UMSARS I score that is not greater than said first UMSARS I score.